Grass­ley to FTC: In­ves­ti­gate the role of PBMs on out-of-pock­et costs

Fol­low­ing the Fed­er­al Trade Com­mis­sion’s de­ci­sion last month to not in­ves­ti­gate phar­ma mid­dle­men, or phar­ma­cy ben­e­fit man­agers, Iowa Re­pub­li­can Sen. Chuck Grass­ley

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER